PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 182-189
DOI: 10.1055/s-0041-1732825
How I Treat

How I Treat Adult Acute Myeloid Leukemia

Tapan K. Saikia
1   Department of Medical Oncology, Prince Aly Khan Hospital, Mumbai, Maharashtra, India Medical ,Oncology Prince Aly Khan Hospital, Mumbai, Maharashtra, India .
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Introduction

In the mind of a reader, the first query would be, do I need to read another review article written by an Indian physician when I get to read everything on the multiple platforms on the internet? Such reaction is a valid one, given the avalanche of information and limited time available to read. Nevertheless, on request of the editorial board I accepted the challenge, and have included some relevant Indian publications.

Acute myeloid leukemia (AML) is a heterogeneous disorder and a very challenging pathology, though not fully unraveled yet.[1] [2] [3] [4] [5] While nonrandom cytogenetic and molecular abnormalities have provided opportunity for a better classification, we still have a sizeable number of cases in whom the pathology is poorly understood, and they continue to receive old chemotherapy regimens and hematopoietic stem cell transplantation (HSCT) whenever possible. Additionally, incidence of Myelodysplastic syndrome (MDS) associated AML and therapy-related AML is not insignificant; a subset of patient pausing maximum challenge.[6] [7] [8]

Acute promyelocytic leukemia (APL) can now be treated very effectively with nonchemotherapy-based regimens and a small subset deriving added benefit from inclusion of chemotherapy drugs like daunorubicin, idarubicin, and antibody drug conjugate gemtuzumab ozogamycin (GO).[9] [10] [11] [12] I will not discuss about APL in this review, as it needs a dedicated article.



Publikationsverlauf

Artikel online veröffentlicht:
06. August 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
    CrossrefPubMedGoogle Scholar
  • 2 Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373 (12) 1136-1152
    CrossrefPubMedGoogle Scholar
  • 3 Ley TJ, Miller C, Ding L. et al. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368 (22) 2059-2074
    CrossrefPubMedGoogle Scholar
  • 4 Welch JS, Ley TJ, Link DC. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150 (02) 264-278
    CrossrefPubMedGoogle Scholar
  • 5 Patel JP, Gönen M, Figueroa ME. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366 (12) 1079-1089
    CrossrefPubMedGoogle Scholar
  • 6 Jan M, Snyder TM, Corces-Zimmerman MR. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4 (149) 149-ra118
    Google Scholar
  • 7 Krönke J, Bullinger L, Teleanu V. et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122 (01) 100-108
    CrossrefPubMedGoogle Scholar
  • 8 Jaiswal S, Fontanillas P, Flannick J. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371 (26) 2488-2498
    CrossrefPubMedGoogle Scholar
  • 9 Sanz MA, Grimwade D, Tallman MS. et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (09) 1875-1891
    CrossrefPubMedGoogle Scholar
  • 10 Osman AEG, Anderson J, Churpek JE. et al. Treatment of acute promyelocytic leukemia in adults. J Oncol Pract 2018; 14 (11) 649-657
    CrossrefPubMedGoogle Scholar
  • 11 Lo-Coco F, Avvisati G, Vignetti M. et al. Gruppo Italiano Malattie Ematologiche dell’Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369 (02) 111-121
    CrossrefPubMedGoogle Scholar
  • 12 Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis 2011; 3 (01) 2011056
    CrossrefPubMedGoogle Scholar
  • 13 Döhner H, Estey E, Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129 (04) 424-447
    CrossrefPubMedGoogle Scholar
  • 14 Klastersky J, de Naurois J, Rolston K. et al. ESMO Guidelines Committee. management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27 (Suppl. 05) v111-v118
    CrossrefPubMedGoogle Scholar
  • 15 Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142 (12, pt 1) 979-995
    CrossrefPubMedGoogle Scholar
  • 16 Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2 (04) 231-242
    CrossrefPubMedGoogle Scholar
  • 17 Cornely OA, Maertens J, Winston DJ. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (04) 348-359
    CrossrefPubMedGoogle Scholar
  • 18 Mitchell S, Li X, Woods M. et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 2016; 22 (05) 702-716
    CrossrefPubMedGoogle Scholar
  • 19 Mayer RJ, Davis RB, Schiffer CA. et al. Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331 (14) 896-903
    CrossrefPubMedGoogle Scholar
  • 20 Sekeres MA, Guyatt G, Abel G. et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv 2020; 4 (15) 3528-3549
    CrossrefPubMedGoogle Scholar
  • 21 Walter RB, Othus M, Borthakur G. et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29 (33) 4417-4423
    CrossrefPubMedGoogle Scholar
  • 22 Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol 2015; 94 (07) 1127-1138
    CrossrefPubMedGoogle Scholar
  • 23 Juliusson G, Antunovic P, Derolf A. et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113 (18) 4179-4187
    CrossrefPubMedGoogle Scholar
  • 24 Juliusson G, Abrahamsson J, Lazarevic V. et al. Swedish AML Group and the Swedish Childhood Leukemia Group. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia 2017; 31 (03) 728-731
    CrossrefPubMedGoogle Scholar
  • 25 Dombret H, Seymour JF, Butrym A. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126 (03) 291-299
    CrossrefPubMedGoogle Scholar
  • 26 Othus M, Kantarjian H, Petersdorf S. et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia 2014; 28 (02) 289-292
    CrossrefPubMedGoogle Scholar
  • 27 Sorror M, Storer B, Elsawy M. et al. Intensive versus non-intensive induction therapy for patients (pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic models. Blood 2016; 128: 216
    CrossrefGoogle Scholar
  • 28 Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol 2018; 93 (10) 1267-1291
    CrossrefPubMedGoogle Scholar
  • 29 Burnett AK, Russell NH, Hills RK. et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31 (27) 3360-3368
    CrossrefPubMedGoogle Scholar
  • 30 Lee J-H, Kim H, Joo Y-D. et al. Cooperative Study Group A for Hematology. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy foe newly diagnosed acute myeloid leukemia. J Clin Oncol 2017; 35 (24) 2754-2763
    CrossrefPubMedGoogle Scholar
  • 31 Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013; 121 (01) 26-28
    CrossrefPubMedGoogle Scholar
  • 32 Østgård LSG, Lund JL, Nørgaard JM. et al. Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia: a national population-based cohort study. Biol Blood Marrow Transplant 2018; 24 (02) 314-323
    CrossrefPubMedGoogle Scholar
  • 33 Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016; 51 (10) 1283-1300
    CrossrefPubMedGoogle Scholar
  • 34 Appelbaum FR. Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol 2017; 30 (04) 320-326
    CrossrefPubMedGoogle Scholar
  • 35 Gooley TA, Chien JW, Pergam SA. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363 (22) 2091-2101
    CrossrefPubMedGoogle Scholar
  • 36 Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127 (01) 62-70
    CrossrefPubMedGoogle Scholar
  • 37 Kröger N, Iacobelli S, Franke GN. et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial. J Clin Oncol 2017; 35 (19) 2157-2164
    CrossrefPubMedGoogle Scholar
  • 38 Deeg HJ, Stevens EA, Salit RB. et al. Transplant conditioning with Treosulfan/Fludarabine with or without Total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 2018; 24 (05) 956-963
    CrossrefPubMedGoogle Scholar
  • 39 Scott BL, Pasquini MC, Logan BR. et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017; 35 (11) 1154-1161
    CrossrefPubMedGoogle Scholar
  • 40 Fasslrinner F, Schetelig J, Burchert A. et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol 2018; 5 (04) e161-e169
    CrossrefPubMedGoogle Scholar
  • 41 Ivey A, Hills RK, Simpson MA. et al. UK National Cancer Research Institute AML Working Group. Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374 (05) 422-433
    CrossrefPubMedGoogle Scholar
  • 42 Jongen-Lavrencic M, Grob T, Hanekamp D. et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 2018; 378 (13) 1189-1199
    CrossrefPubMedGoogle Scholar
  • 43 Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 2018; 19 (05) 269-285
    CrossrefPubMedGoogle Scholar
  • 44 Patkar N, Kakirde C, Bhanshe P. et al. Utility of immunophenotypic measurable residual disease in adult acute myeloid leukemia- Real-World-Context. Front Oncol 2019; 9: 450
    CrossrefPubMedGoogle Scholar
  • 45 Schuurhuis GJ, Heuser M, Freeman S. et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131 (12) 1275-1291
    CrossrefPubMedGoogle Scholar
  • 46 Riezzo I, Pascale N, La Russa R, Liso A, Salerno M, Turillazzi E. Donor selection for allogeneic hematopoietic stem cell transplantation: clinical and ethical considerations. Stem Cells Int 2017; 2017: 5250790
    CrossrefPubMedGoogle Scholar
  • 47 Shouval R, Fein JA, Labopin M. et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol 2019; 6 (11) e573-e584
    CrossrefPubMedGoogle Scholar
  • 48 Kindwall-Keller TL, Ballen KK. Alternative donor graft sources for adults with hematologic malignancies: a donor for all patients. Oncologist 2017; 22 (09) 1125-1134
    CrossrefPubMedGoogle Scholar
  • 49 Stone RM, Mandrekar SJ, Sanford BL. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377 (05) 454-464
    CrossrefPubMedGoogle Scholar
  • 50 Voso MT, Larson RA, Jones D. et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv 2020; 4 (19) 4945-4954
    CrossrefPubMedGoogle Scholar
  • 51 Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 2017; 130 (23) 2469-2474
    CrossrefPubMedGoogle Scholar
  • 52 Burd A, Levine RL, Ruppert AS. et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med 2020; 26 (12) 1852-1858
    CrossrefPubMedGoogle Scholar
  • 53 Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol 2019; 12 (01) 100
    CrossrefPubMedGoogle Scholar
  • 54 Röllig C, Serve H, Hüttmann A. et al. Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 2015; 16 (16) 1691-1699
    CrossrefPubMedGoogle Scholar
  • 55 Duchmann M, Micol J-B, Duployez N. et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood 2021; 137 (20) 2827-2837
    CrossrefPubMedGoogle Scholar
  • 56 Quintás-Cardama A, Ravandi F, Liu-Dumlao T. et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012; 120 (24) 4840-4845
    CrossrefPubMedGoogle Scholar
  • 57 DiNardo CD, Jonas BA, Pullarkat V. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020; 383: 17-629
    CrossrefPubMedGoogle Scholar
  • 58 DiNardo CD, Pollyea DA, Jonas BA. et al. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. Blood 2017; 130: 2628-2638
    Google Scholar
  • 59 DiNardo CD, Rausch CR, Benton C. et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018; 93 (03) 401-407
    CrossrefPubMedGoogle Scholar
  • 60 Fathi AT, DiNardo CD, Kline I. et al. AG221-C-001 Study Investigators. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol 2018; 4 (08) 1106-1110
    CrossrefPubMedGoogle Scholar
  • 61 DiNardo CD, Stein EM, de Botton S. et al. Durable remissions with ivosidenib in IDH-1-mutated relapsed or refractory AML. N Engl J Med 2018; 378 (25) 2386-2398
    CrossrefPubMedGoogle Scholar
  • 62 Daver N, Boddu P, Garcia-Manero G. et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2018; 32 (05) 1094-1105
    CrossrefPubMedGoogle Scholar
  • 63 Craddock C, Labopin M, Robin M. et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2016; 101 (07) 879-883
    CrossrefPubMedGoogle Scholar
  • 64 Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L, Vundinti B. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India. Ann Hematol 2012; 91 (11) 1703-1712
    CrossrefPubMedGoogle Scholar
  • 65 Büchner T, Berdel WE, Schoch C. et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24 (16) 2480-2489
    CrossrefPubMedGoogle Scholar
  • 66 Mao C, Fu XH, Yuan JQ. et al. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database Syst Rev 2015; 201511 (11) CD01-0248
    Google Scholar
  • 67 Oran B, de Lima M, Garcia-Manero G. et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 2020; 4 (21) 5580-5588
    CrossrefPubMedGoogle Scholar
  • 68 Marcucci G, Geyer S, Laumann K. et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv 2020; 4 (04) 696-705
    CrossrefPubMedGoogle Scholar
  • 69 Philip C, George B, Ganapule A. et al. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 2015; 170 (01) 110-117
    CrossrefPubMedGoogle Scholar
  • 70 Ganapule A, Nemani S, Korula A. et al. Allogeneic stem cell transplantation for acute myeloid leukemia: evolution of an effective strategy. J Glob Oncol 2017; 3 (06) 773-781
    CrossrefPubMedGoogle Scholar
  • 71 George B, Menon H, Bhurani D. et al. A prospective observational multi-institutional study on fungal infections following chemotherapy for acute myeloid leukemia (MISFIC Study): a real world scenario from India. Indian J Hematol Blood Transfus 2020; 36 (01) 97-103
    CrossrefPubMedGoogle Scholar
  • 72 Bahl A, Sharma A, Raina V. et al. Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. Asia Pac J Clin Oncol 2015; 11 (03) 242-252
    CrossrefPubMedGoogle Scholar
  • 73 Kalaiyarasi JP, Ganesan P, Kannan K. et al. Outcomes of intensive treatment of adult acute myeloid leukemia patients: a retrospective study from a single centre. Indian J Hematol Blood Transfus 2019; 35 (02) 248-254
    CrossrefPubMedGoogle Scholar
  • 74 Saikia TK, Bakshi A, Bhagwat R. et al. Outcome of acute myeloid leukaemia in adults: a retrospective analysis. Natl Med J India 2005; 18 (01) 12-15
    PubMedGoogle Scholar
  • 75 Tandon N, Banavali S, Menon H, Gujral S, Kadam PA, Bakshi A. Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review. Indian J Cancer 2013; 50 (02) 154-158
    CrossrefPubMedGoogle Scholar
  • 76 Kapoor A, Beniwal SK, Kalwar A. et al. Metronomic therapy with oral 6-mercaptourine in elderly acute myeloid leukemia. South Asian J Cancer 2016; 5: 70-72
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 77 Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015; 126 (03) 319-327
    CrossrefPubMedGoogle Scholar
  • 78 Burnett AK, Goldstone A, Hills RK. et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 2013; 31 (10) 1293-1301
    CrossrefPubMedGoogle Scholar
  • 79 Duval M, Klein JP, He W. et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28 (23) 3730-3738
    CrossrefPubMedGoogle Scholar
  • 80 Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality. ? Haematologica 2019; 104 (07) 1302-1308
    CrossrefPubMedGoogle Scholar
  • 81 Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood 2015; 126 (26) 2790-2797
    CrossrefPubMedGoogle Scholar